title: CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
abstract: BACKGROUND
  CD4+ T-cell recovery in patients with continuous suppression of plasma HIV-1 viral load (VL) is highly variable. This study aimed to identify predictive factors for long-term CD4+ T-cell increase in treatment-naive patients starting combination antiretroviral therapy (cART).
  
  
  METHODS
  Treatment-naive patients in the Swiss HIV Cohort Study reaching two VL measurements <50 copies/ml >3 months apart during the 1st year of cART were included (n=1816 patients). We studied CD4+ T-cell dynamics until the end of suppression or up to 5 years, subdivided into three periods: 1st year, years 2-3 and years 4-5 of suppression. Multiple median regression adjusted for repeated CD4+ T-cell measurements was used to study the dependence of CD4+ T-cell slopes on clinical covariates and drug classes.
  
  
  RESULTS
  Median CD4+ T-cell increases following VL suppression were 87, 52 and 19 cells/microl per year in the three periods. In the multiple regression model, median CD4+ T-cell increases over all three periods were significantly higher for female gender, lower age, higher VL at cART start, CD4+ T-cell <650 cells/microl at start of the period and low CD4+ T-cell increase in the previous period. Patients on tenofovir showed significantly lower CD4+ T-cell increases compared with stavudine.
  
  
  CONCLUSIONS
  In our observational study, long-term CD4+ T-cell increase in drug-naive patients with suppressed VL was higher in regimens without tenofovir. The clinical relevance of these findings must be confirmed in, ideally, clinical trials or large, collaborative cohort projects but could influence treatment of older patients and those starting cART at low CD4+ T-cell levels.
authors.affiliation: Basel Institute for Clinical Epidemiology, University Hospital Basel, Switzerland.
authors.forename: Marcel
authors.initials: M
authors.lastname: Wolbers
authors.forename: Manuel
authors.initials: M
authors.lastname: Battegay
authors.forename: Bernard
authors.initials: B
authors.lastname: Hirschel
authors.forename: Hansjakob
authors.initials: H
authors.lastname: Furrer
authors.forename: Matthias
authors.initials: M
authors.lastname: Cavassini
authors.forename: Barbara
authors.initials: B
authors.lastname: Hasse
authors.forename: Pietro L
authors.initials: PL
authors.lastname: Vernazza
authors.forename: Enos
authors.initials: E
authors.lastname: Bernasconi
authors.forename: Gilbert
authors.initials: G
authors.lastname: Kaufmann
authors.forename: Heiner C
authors.initials: HC
authors.lastname: Bucher
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use; D000068698:Tenofovir; D013997:Time Factors; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine